Background and Study Aims: Primary sclerosing cholangitis (PSC) is associated with the development of cholangiocarcinoma
in up to 10 % of patients. Cholangiography or endoscopic tissue sampling does not
reliably distinguish between cholangiocarcinoma and a benign dominant bile duct stenosis.
The aim of the present study was to assess the value of cholangioscopy for distinguishing
between benign and malignant dominant stenoses in PSC patients.
Patients and Methods: Fifty-three PSC patients with dominant bile duct stenoses were prospectively studied.
Transpapillary cholangioscopy and endoscopic tissue sampling were carried out in addition
to endoscopic retrograde cholangiography (ERC). The cholangiography and cholangioscopic
findings were classified as malignant or benign by the investigators. A final diagnosis
of malignant stenosis was based on positive histology and/or cytology, whereas a benign
condition was assumed in cases of negative tissue sampling and uneventful extended
clinical follow-up.
Results: Twelve PSC patients (23 %) had dominant bile duct stenoses caused by cholangiocarcinoma,
whereas 41 of the 53 patients (77 %) had benign dominant bile duct stenoses. Cholangioscopy
was significantly superior to ERC for detecting malignancy in terms of its sensitivity
(92 % vs. 66 %; P = 0.25), specificity (93 % vs. 51 %; P < 0.001), accuracy (93 % vs. 55 %; P < 0.001), positive predictive value (79 % vs. 29 %; P < 0.001), and negative predictive value (97 % vs. 84 %; P < 0.001). Transpapillary cholangioscopy is more sensitive and specific for characterizing
malignant bile duct stenosis in comparison with endoscopic brush cytology.
Conclusions: Transpapillary cholangioscopy significantly increases the ability to distinguish
between malignant and benign dominant bile duct stenoses in patients with PSC.
References
- 1
Chapman R WG, Marborgh B A, Rhodes J M. et al .
Primary sclerosing cholangitis: a review of clinical features, cholangiography and
hepatic histology.
Gut.
1980;
21
870-877
- 2
La Russo N F, Wiesner R H, Ludwig J. et al .
Primary sclerosing cholangitis.
N Engl J Med.
1984;
310
899-903
- 3
Farrant J M, Hayllar K M, Wilkinson M L. et al .
Natural history and prognostic variables in primary sclerosing cholangitis.
Gastroenterology.
1991;
100
1710-1717
- 4
Broomé U, Olsson R, Lööf L. et al .
Natural history and prognostic factor in 305 Swedish patients with primary sclerosing
cholangitis.
Gut.
1996;
38
610-615
- 5
Ponsioen C Y, Vrouenraets S ME, Prawirodidjo W. et al .
Natural history of primary sclerosing cholangitis and prognostic value of cholangiography
in a Dutch population.
Gut.
2002;
51
562-566
- 6
Rosen C B, Nagorney D M, Wiesner R H. et al .
Cholangiocarcinoma complicating primary sclerosing cholangitis.
Ann Surg.
1991;
213
21-25
- 7
Abu-Elmagd K M, Selby R, Iwatsuki S. et al .
Cholangiocarcinoma and sclerosing cholangitis: clinical characteristics and effect
on survival after liver transplantation.
Transplant Proc.
1993;
25
1124-1125
- 8
Knechtle S J, D’Alessandro A M, Harms B A. et al .
Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer
in patients undergoing liver transplantation.
Surgery.
1995;
118
615-620
- 9
Nashan B, Schlitt H J, Tusch G. et al .
Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation.
Hepatology.
1996;
23
1105-1111
- 10
MacCarty R L, La Russo N F, May G R. et al .
Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances.
Radiology.
1985;
156
43-46
- 11
Stiehl A, Rudolph G, Klöters-Plachky P. et al .
Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis
treated with ursodeoxycholic acid: outcome after endoscopic treatment.
J Hepatol.
2002;
36
151-156
- 12
Berquist A, Glaumann H, Persson B. et al .
Risk factors and clinical presentation of hepatobiliary carcinoma in patients with
primary sclerosing cholangitis: a case-control study.
Hepatology.
1998;
27
311-316
- 13
Ponsioen C Y, Vrouenraets S ME, van Milligen de Witt A WM. et al .
Value of brush cytology for dominant strictures in primary sclerosing cholangitis.
Endoscopy.
1999;
31
305-309
- 14
Lindberg B, Arnelo U, Bergquist A. et al .
Diagnosis of biliary strictures in conjugation with endoscopic retrograde cholangiopancreatography,
with special reference to patients with primary sclerosing cholangitis.
Endoscopy.
2002;
34
909-916
- 15
Nichols J C, Gores G J, LaRusso N F. et al .
Diagnostic role of serum CA19 - 9 for cholangiocarcinoma in patients with primary
sclerosing cholangitis.
Mayo Clinic Proc.
1993;
68
874-879
- 16
Ramage J K, Donaghy A, Farrant J M. et al .
Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing
cholangitis.
Gastroenterology.
1995;
108
865-869
- 17
Björnsson E, Kilander A, Olsson R.
Ca19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary
sclerosing cholangitis.
Liver.
1999;
19
510-508
- 18
Hultcrantz R, Olsson R, Danielsson A. et al .
A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma
in patients with primary sclerosing cholangitis.
J Hepatol.
1999;
30
669-673
- 19
Nimura Y, Kamiya J, Hayakawa N. et al .
Cholangioscopic differentiation of biliary strictures and polyps.
Endoscopy.
1989;
21
351-356
- 20
Nimura Y.
Staging of biliary carcinoma: cholangiography and cholangioscopy.
Endoscopy.
1993;
25
76-80
- 21
Seo D W, Kim M H, Lee S K. et al .
Usefulness of cholangioscopy in patients with focal stricture of the intrahepatic
duct unrelated to intrahepatic stones.
Gastrointest Endosc.
1999;
49
204-209
- 22
Christensen M, Matzen P, Schulze S. et al .
Complications of ERCP: a prospective study.
Gastrointest Endosc.
2004;
60
721-731
P. N. Meier, M. D.
Dept. of Gastroenterology, Hepatology and Endocrinology
Medizinische Hochschule Hannover · Carl-Neuberg-Strasse 1 · 30625 Hannover · Germany
Fax: +49-511-532-4896·
Email: meier.peter@mh-hannover.de
